Medprin Biotech
Develops and manufactures regenerative implantable medical devices using biological 3D printing and nano-bionics technology for human tissue recovery, replacement, and regeneration.
- CEO / Founder
- Yuyu Yuan
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $35M
- Latest Round
- IPO - $35M - July 2021
- Key Investors
- Public Investors
Technology & Products
Key Products
ReDura™ Synthetic Dural Substitute, NeoDura™ Novel Dural Patch, Recranio™ Cranio-Maxillofacial repair system, StypCel™ Absorbable Hemostat.
Technological Advantage
Proprietary biological 3D printing process enables precise fabrication of patient-specific regenerative implants, protected by extensive patent portfolio (85 patents granted, 225 applications).
Differentiation
Value Proposition
Reduces surgical complications and improves patient outcomes through precision-engineered, patient-specific implantable devices that promote tissue regeneration, with CE-marked products sold in over 70 countries.
How They Differentiate
Focuses exclusively on regenerative implantable devices using biological 3D printing, unlike competitors' broader medical device portfolios; offers patient-specific customization through additive manufacturing vs. standard off-the-shelf products.
Market & Competition
Target Customers
Hospitals, healthcare providers, medical device distributors
Industry Verticals
Medical Device; Healthcare; Regenerative Medicine
Competitors
Baxter International Inc., Boston Scientific, Cook Medical, NeuraMedica, Allevi.
Growth & Milestones
Growth Metrics
Products sold to more than 70 countries and regions; over 300 patent applications worldwide and 150 patents authorized; 1,229 LinkedIn followers
Major Milestones
Founded in 2008; CE-marked products sold in over 70 countries; 85 patents authorized; 225 patent applications worldwide
Notable Customers
Medprin's products are sold in over 100 countries and have benefited more than 1,600,000 patients.